Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Net Margin (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Net Margin for 16 consecutive years, with 18.92% as the latest value for Q1 2026.

  • For Q1 2026, Net Margin fell 3183.0% year-over-year to 18.92%; the TTM value through Mar 2026 reached 6.07%, down 1326.0%, while the annual FY2025 figure was 12.89%, 781.0% down from the prior year.
  • Net Margin hit 18.92% in Q1 2026 for Corcept Therapeutics, down from 11.83% in the prior quarter.
  • Across five years, Net Margin topped out at 33.96% in Q3 2022 and bottomed at 18.92% in Q1 2026.
  • Average Net Margin over 5 years is 17.8%, with a median of 18.74% recorded in 2024.
  • Year-over-year, Net Margin skyrocketed 696bps in 2023 and then plummeted -3183bps in 2026.
  • Corcept Therapeutics' Net Margin stood at 16.04% in 2022, then skyrocketed by 43bps to 23.0% in 2023, then decreased by -27bps to 16.71% in 2024, then decreased by -29bps to 11.83% in 2025, then crashed by -260bps to 18.92% in 2026.
  • According to Business Quant data, Net Margin over the past three periods came in at 18.92%, 11.83%, and 9.32% for Q1 2026, Q4 2025, and Q3 2025 respectively.